Filed Pursuant to Rule 424B2
Registration No. 333-236429
Prospectus Supplement
(To Prospectus dated February 14, 2020)
$150,000,000
Kemper Corporation
5.875% Fixed-Rate Reset Junior Subordinated Debentures due 2062
We are offering $150,000,000 of our 5.875% fixed-rate reset junior subordinated debentures due 2062, or the “debentures.” The debentures will bear interest (i) from and including the date of original issue to, but excluding, March 15, 2027, at the fixed rate of 5.875% per annum and (ii) from, and including, March 15, 2027, during each Reset Period (as defined below), at a rate per annum equal to the Five-Year Treasury Rate (as defined below) as of the most recent Reset Interest Determination Date (as defined below) plus 4.140% to be reset on each Reset Date (as defined below). We will pay interest on the debentures quarterly on March 15, June 15, September 15 and December 15 of each year, beginning on June 15, 2022. We may defer interest payments during one or more deferral periods for up to five consecutive years each as described in this prospectus supplement. See “Description of Debentures—Option to Defer Interest Payments.” The debentures will mature on March 15, 2062.
We may redeem the debentures, in whole or in part on the First Reset Date (as defined below) or any time thereafter, at a redemption price equal to the principal amount of the debentures being redeemed plus any accrued and unpaid interest thereon (including compounded interest, if any) to, but excluding, the date of redemption; provided that if the debentures are not redeemed in whole, at least $25 million aggregate principal amount of the debentures must remain outstanding after giving effect to such redemption.
We may redeem the debentures, in whole but not in part, at any time prior to March 15, 2027, within 90 days of the occurrence of a Tax Event (as defined in “Description of Debentures—Optional Redemption of the Debentures”), at a redemption price equal to the principal amount plus any accrued and unpaid interest thereon (including compounded interest, if any) to, but excluding, the date of redemption.
We may redeem the debentures, in whole but not in part, at any time prior to March 15, 2027, within 90 days of the occurrence of a Regulatory Capital Event (as defined in “Description of Debentures—Optional Redemption of the Debentures”), at a redemption price equal to the principal amount plus any accrued and unpaid interest thereon (including compounded interest, if any) to, but excluding, the date of redemption.
We may redeem the debentures, in whole but not in part, at any time prior to March 15, 2027, within 90 days of the occurrence of a Rating Agency Event (as defined in “Description of Debentures—Optional Redemption of the Debentures”), at a redemption price equal to 102% of the principal amount plus any accrued and unpaid interest thereon (including compounded interest, if any) to, but excluding, the date of redemption.
The debentures will be unsecured and will rank in right of payment and upon our liquidation junior to all of our current and future senior indebtedness on the terms set forth in the indenture pursuant to which the debentures will be issued. The debentures will not be obligations of or guaranteed by any of our subsidiaries. As a result, the debentures will also be effectively subordinated to all debt and other liabilities of our subsidiaries.
Beneficial interests in the debentures will be issued in book-entry form in denominations of $25 and multiples of $25 in excess thereof.
We will apply for the listing of the debentures on the New York Stock Exchange (the “NYSE”) under the symbol “KMPB.” If approved for listing, trading of the debentures on the NYSE is expected to commence within 30 days after they are first issued.
Investing in the debentures involves risks. See “Risk Factors” beginning on page S-7 of this prospectus supplement and the “Risk Factors” section in our Annual Report on Form 10-K for the year ended December 31, 2021, which is incorporated by reference herein, for a discussion of certain risks that you should consider in connection with an investment in the debentures.
None of the Securities and Exchange Commission, any state securities commission or any other regulatory body has approved or disapproved of these securities or determined if this prospectus supplement or the accompanying prospectus is truthful or complete. Any representation to the contrary is a criminal offense.
| | | | | | | | | | | | |
| | Public Offering Price(1) | | | Underwriting Discount(2) | | | Proceeds, Before Expenses, to Kemper Corporation(3) | |
Per Debenture(4) | | $ | 25.00 | | | $ | 0.7875 | | | $ | 24.2125 | |
Total | | $ | 150,000,000 | | | $ | 4,725,000 | | | $ | 145,275,000 | |
(1) | Plus accrued interest from March 10, 2022, if settlement occurs after that date. |
(2) | The underwriting discount will be $0.50 per debenture for sales to institutions and, to the extent of such institutional sales, the total underwriting discount will be less than the amount set forth in the above table. As a result of sales to institutions, the total proceeds to us before estimated expenses will be $145,562,500. |
(3) | Assumes no exercise of the underwriters’ over-allotment option described below. |
(4) | Amounts shown are per $25 principal amount of debentures. |
We have granted the underwriters an option, exercisable for 30 days from the date of this prospectus supplement, to purchase up to an additional $22,500,000 aggregate principal amount of debentures solely to cover over-allotments at the initial public offering price set forth on the cover page of this prospectus supplement less the applicable underwriting discount. If the underwriters exercise this option in full, upon the exercise of the option, the total public offering price will be $172,500,000, the total underwriting discount will be $5,146,250 and the total proceeds, before expenses, to Kemper Corporation, will be $167,353,750 (assuming no option sales are made to institutions).
The underwriters expect to deliver the debentures through the facilities of The Depository Trust Company for the accounts of its participants, which may include Clearstream Banking S.A. and Euroclear Bank S.A./N.V., against payment in New York, New York on or about March 10, 2022.
Joint Bookrunners
| | | | |
Wells Fargo Securities | | BofA Securities | | Morgan Stanley |
Co-Managers
| | | | | | |
| |
Goldman Sachs & Co. LLC | | J.P. Morgan |
| | | |
Ramirez & Co., Inc. | | Raymond James | | Regions Securities LLC | | Siebert Williams Shank |
The date of this prospectus supplement is March 3, 2022.